| Home | E-Submission | Sitemap | Contact Us |  
Clinical and Experimental Otorhinolaryngology > Volume 15(4); 2022 > Article
Kwon: Prediction of Occult Lymph Node Metastasis in Early Tongue Cancer
Tongue cancer has a relatively high occult lymph node metastasis (OLNM) rate of 24.4%, even in early stages (T1–T2), and cervical lymph node metastasis is significantly correlated with poor clinical outcomes [1,2]. Therefore, the prediction and treatment of cervical lymph node metastasis are important, even in patients with early-stage tongue cancer. A recent systematic review concluded that elective neck dissection (END), compared with observation, in T1–T2 early tongue cancer could significantly reduce locoregional failure and increase the disease-free survival (DFS) rate [3]. Nonetheless, in light of the risk of side effects and complications after END, detailed preoperative criteria for patient selection will be required.
The National Comprehensive Cancer Network guidelines recommend END or sentinel lymph node biopsy for neck management in early tongue cancer cases when the depth of invasion (DOI) of the primary tumor is greater than 3 mm, given the risk of OLNM [4]. Although DOI and the worst pattern of invasion are currently used as predictive models for OLNM in oral cancer, applying those criteria to actual preoperative evaluations is problematic because they are based on postoperative pathological results. Preoperative DOI measurements using imaging tests such as magnetic resonance imaging or intraoperative ultrasonography have been reported to have relevance to the postoperative pathological results; however, there are practical limitations in accurately assessing the DOI of small lesions using radiological methods [5]. A recently introduced deep learning-based modeling method can increase the prediction accuracy of OLNM, but it is difficult to apply this model in the real clinical field considering time and cost [6]. Therefore, in addition to the above indicators, it is necessary to discover new markers for preoperative OLNM prediction.
Lee et al. [7] recently reported the significance of defensin-associated genes as predictors of OLNM in early tongue cancer. The authors performed RNA sequencing on primary tumor samples from 35 tongue cancer patients and analyzed differentially expressed genes (DEGs) according to OLNM status in samples after END. Their analyses confirmed that lower expression of defensin-associated genes (DEFB4A, DEFB103B, and DEFB4B) in the primary tumor could be associated with an increased risk of OLNM in early tongue cancer, suggesting that those genes could be used as biomarkers [7]. Another study published by the same author found that the expression of actin-associated genes such as ACTA1 had a significant relationship with regional metastasis in early tongue cancer [8]. Yang et al. [9] reported that the expression of TNFRSF10C, a gene involved in immune-related pathways, had a significant relationship with OLNM and DFS, and that the log2 ratio of copy number variation of the gene could suggest a favorable prognosis in patients with node-negative early tongue cancer.
In early tongue cancer, preoperative biomarker-based OLNM prediction for the primary tumor may provide more precise information regarding neck management. Nonetheless, it is questionable whether specific genetic information can be accurately confirmed from a small specimen obtained from a punch biopsy before surgery, and another limitation is that an accurate cut-off value for whether to perform END based on the level of marker expression has not yet been determined. Consequently, it is thought that the practical application of genetic biomarkers in the clinical setting will be possible in the future when technological advances are made to reduce the time and cost required to confirm DEG results before surgery in early tongue cancer patients.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Mucke T, Mitchell DA, Wagenpfeil S, Ritschl LM, Wolff KD, Kanatas A. Incidence and outcome for patients with occult lymph node involvement in T1 and T2 oral squamous cell carcinoma: a prospective study. BMC Cancer. 2014 May;14:346.
crossref pmid pmc pdf
2. Choi KY, Park SC, Kim JH, Lee DJ. The occult nodal metastasis rate of early tongue cancer (T1-T2): a protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2021 Jan;100(3):e24327.
pmid pmc
3. Abu-Ghanem S, Yehuda M, Carmel NN, Leshno M, Abergel A, Gutfeld O, et al. Elective neck dissection vs observation in early-stage squamous cell carcinoma of the oral tongue with no clinically apparent lymph node metastasis in the neck: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2016 Sep;142(9):857–65.
crossref pmid
4. National Comprehensive Cancer Network. NCCN Guidelines for Head and Neck Cancers ver. 2. 2022 [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2022 [cited 2022 Nov 1]. Available from: https://www.nccn.org/guidelines.

5. Li M, Yuan Z, Tang Z. The accuracy of magnetic resonance imaging to measure the depth of invasion in oral tongue cancer: a systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2022 Apr;51(4):431–40.
crossref pmid
6. Shan J, Jiang R, Chen X, Zhong Y, Zhang W, Xie L, et al. Machine learning predicts lymph node metastasis in early-stage oral tongue squamous cell carcinoma. J Oral Maxillofac Surg. 2020 Dec;78(12):2208–18.
crossref pmid
7. Lee DY, Hah JH, Jeong WJ, Chung EJ, Kwon TK, Ahn SH, et al. The expression of defensin-associated genes may be correlated with lymph node metastasis of early-stage tongue cancer. Clin Exp Otorhinolaryngol. 2022 Nov;15(4):372–9.
crossref pmid pmc pdf
8. Lee DY, Kang Y, Im NR, Kim B, Kwon TK, Jung KY, et al. Actin-associated gene expression is associated with early regional metastasis of tongue cancer. Laryngoscope. 2021 Apr;131(4):813–9.
crossref pmid pdf
9. Yang X, Fang L, Zhang C. CNV analysis of the correlation between preoperative lymph node metastasis and prognosis of early tongue cancer. J Cancer. 2021 Aug;12(20):6135–44.
crossref pmid pmc
Editorial Office
Korean Society of Otorhinolaryngology-Head and Neck Surgery
103-307 Park Tower officetel, Yongsan-dong 5-ga, Yongsan-gu, Seoul 04385, Korea
TEL: +82-2-711-9091   FAX: +82-2-3487-6603   E-mail: editor.eceo@gmail.com
Copyright © Korean Society of Otorhinolaryngology-Head and Neck Surgery.                 Developed in M2PI
Close layer
prev next